Grifols

Update in progress

GRFS (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryDrug Manufacturers - General

Grifols, S.A. and its subsidiaries develop, produce, and market plasma-derived medicines worldwide. It operates through four segments—Biopharma, Diagnostic, Bio Supplies, and Others—and offers hemoderivatives for immunology, infectious diseases, hepatology, critical care, pulmonology, hematology, and neurology. It provides diagnostic equipment and services, blood and plasma products to life-science customers, hospital solutions, and manufacturing services. Headquartered in Barcelona, founded in 1909.

Company score

Sentiment: 0.50; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.60; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.08; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.37; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.15; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.32; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive